1. Generics Bulletin
  2. >>Products

Boehringer Allies With Quallent For Push On Adalimumab

Follows Confirmation Of Teva-Alvotech Involvement In Deal With Cigna’s Evernorth

 
• By Dave Wallace

Boehringer Ingelheim has revealed that it will supply its 50mg/ml adalimumab biosimilar to Quallent Pharmaceuticals in the US, under a recently-announced initiative that also involves Teva and Alvotech’s 100mg/ml Humira rival.

Handshake
Boehringer has announced an adalimumab deal with Quallent

Boehringer Ingelheim will supply its US Humira (adalimumab) interchangeable 50mg/ml biosimilar to Quallent Pharmaceuticals, a private-label distribution division of Cigna’s Evernorth, under a deal that Boehringer has just announced.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products